Thymalin is a complex of low-molecular-weight polypeptides isolated from the thymus (the thymus gland) of cattle. It was developed in the 1970s in Leningrad (now Saint Petersburg) within the "peptide bioregulation" line of work, and since then it has remained one of the most studied thymic preparations in post-Soviet literature as a means of correcting the T-cell arm of immunity [1].
Unlike individual synthetic peptides, thymalin is a heterogeneous fraction rather than one defined molecule. That is why no single amino-acid sequence or unambiguous molar mass exists for it: the biological activity is attributed to a mixture of short peptides in the range of roughly 1 to 10 kDa [1][2].
What it is and its class
Thymalin belongs to the class of thymic peptide bioregulators (immunomodulators). It is regarded as a "natural" extract preparation whose action was later sought to be reduced to individual short peptides. Its related synthetic analogs, thymogen (Glu-Trp) and vilon (Lys-Glu, the KE dipeptide), are synthesized chemically as an attempt to reproduce the fraction's key effects in the form of a defined molecule [2]. That is why the literature often analyzes thymalin as a pair of "natural extract versus synthetic derivatives".
Mechanism of action
The main hypothesis of the mechanism is regulation of T-lymphocyte differentiation. Studies describe that thymic peptides stimulate maturation and differentiation of T cells, affect recognition of peptide-MHC (major histocompatibility complex) complexes, modulate the activity of natural killers (NK) and the cytokine balance (IL-2 and interferon in particular), and also change the intracellular level of cyclic nucleotides in blood lymphocytes [2]. At the molecular level the authors suggest an epigenetic component: an effect of short peptides on the expression of genes related to proliferation and inflammation [1]. In vitro, on the monocytic-macrophage THP-1 line, thymic peptides (including thymalin) changed proliferative activity and inflammatory signaling pathways, in particular the phosphorylation of mitogen-activated kinases [3].
What the research shows
The largest body of data comes from clinics of the post-Soviet region. Thymalin was studied as a means of correcting secondary immunodeficiencies, in chronic infectious and inflammatory conditions, and in a gerontological context. In long-term observation of elderly people, the use of thymic peptides was linked to improved indicators of the immune, cardiovascular and neuroendocrine systems and to a lower incidence of acute respiratory illnesses [4]. Comparative work indicates that both the natural extract and the synthetic analogs activate T-cell differentiation, but differ in their effect on neutrophils: chemotaxis and phagocytosis [2].
These data matter to keep in the proper context. A significant part of the research was carried out mainly by a single scientific school, often without independent replication; by modern evidence criteria (randomized blinded multicenter trials) the methodology of many early works is limited. Thymalin is therefore more correctly described as a promising object for research on immunoregulation and geroprotection than as an agent with clinical efficacy proven by international standards.
Form and handling (research-use)
Longeva supplies thymalin as a research substance (reagent) with an accompanying certificate of analysis (COA). It is a material for laboratory research, not a medicine. The typical form is a lyophilized powder, reconstituted with sterile or bacteriostatic water immediately before the experiment. The lyophilizate is stored dry, in a place protected from light; the reconstituted solution is kept cold, with freeze-thaw cycles minimized. Because this is a heterogeneous peptide fraction, individual batches may differ in composition, so for reproducibility of results it is worth checking against the data of the specific COA. The material is not intended for use by humans or animals, and no medical prescriptions are given here.